Adam Reynolds
Research Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Year:
2026
Year:
2026
Year:
2026
Sex differences in melanoma are prominent, with female having a significant survival advantage. However, it is unclear why we see this survival advantage. Here, we investigate the relationship between sex, clinicopathologic variables, and melanoma specific survival in 1753 single primary melanomas from patients in the GEM (Genes, Environment, and Melanoma) study. Using Cox proportional hazard models and formal mediation analysis, the effect of sex on survival is explained largely by differences in the clinicopathologic features of tumors at diagnosis. Specifically, we find evidence that 86.5% of the effect of sex on melanoma survival is mediated by differences in age at diagnosis, Breslow thickness, ulceration, mitoses, and site (hazard ratio [HR] = 1.85, P < .001). This analysis indicates that the female survival advantage in melanoma is not primarily due to a direct effect of sex (HR = 1.19, P = .42) but is largely a result of an indirect effect of sex mediated by clinicopathologic features.
Year:
2025
Purpose: Patients with stage II and resected stage III melanomas have variable clinical outcomes, providing evidence of underlying biological differences in tumors and/or the patients themselves, beyond stage. The approval of adjuvant immunotherapy for stage IIB/C and resected stage III/IV disease (and adjuvant targeted therapy for resected stage III disease) has created a pressing need to develop biomarkers to accurately distinguish patients at low risk versus high risk for recurrence and death from melanoma. miRNAs are promising biomarkers because of their stability in tissues and fluids and their demonstrated functional and prognostic roles in melanoma. We hypothesized that miRNA expression could be integrated into prognostic models that would classify 5-year survival outcomes more accurately than clinical factors alone. Experimental Design: Using a NanoString miRNA Expression Assay, we analyzed 715 primary melanomas from patients with stage II or stage III disease within the InterMEL consortium and examined associations between miRNA expression and melanoma-specific death. Results: When integrated into clinical prognostic models for 5-year melanoma-specific survival, miRNA signatures improved the area under the receiver operating characteristic curve for patients in stage II from 0.71 for a “clinical factors–only” model to 0.81 for a “clinical plus miRNA” model in an independent test set, an improvement of 0.10 with a 95% confidence interval (0.03–0.19). The improvement was more modest for patients in stage III who were included in the analysis. Conclusions: Incorporating miRNA expression in primary melanomas may enhance the accuracy of clinical prognostic models and potentially aid in the selection of patients with melanoma for adjuvant treatment and clinical trials.
Year:
2025
Purpose: Patients with stage II and resected stage III melanomas have variable clinical outcomes, providing evidence of underlying biological differences in tumors and/or the patients themselves, beyond stage. The approval of adjuvant immunotherapy for stage IIB/C and resected stage III/IV disease (and adjuvant targeted therapy for resected stage III disease) has created a pressing need to develop biomarkers to accurately distinguish patients at low risk versus high risk for recurrence and death from melanoma. miRNAs are promising biomarkers because of their stability in tissues and fluids and their demonstrated functional and prognostic roles in melanoma. We hypothesized that miRNA expression could be integrated into prognostic models that would classify 5-year survival outcomes more accurately than clinical factors alone. Experimental Design: Using a NanoString miRNA Expression Assay, we analyzed 715 primary melanomas from patients with stage II or stage III disease within the InterMEL consortium and examined associations between miRNA expression and melanoma-specific death. Results: When integrated into clinical prognostic models for 5-year melanoma-specific survival, miRNA signatures improved the area under the receiver operating characteristic curve for patients in stage II from 0.71 for a “clinical factors–only” model to 0.81 for a “clinical plus miRNA” model in an independent test set, an improvement of 0.10 with a 95% confidence interval (0.03–0.19). The improvement was more modest for patients in stage III who were included in the analysis. Conclusions: Incorporating miRNA expression in primary melanomas may enhance the accuracy of clinical prognostic models and potentially aid in the selection of patients with melanoma for adjuvant treatment and clinical trials.
Year:
2025
Objectives Comparisons between Indigenous peoples over time and within a particular geographic region can shed light on the impact of environmental transitions on the skeleton, including relative bone strength, sexual dimorphism, and age‐related changes. Here we compare long bone structural properties of the inhabitants of the late prehistoric‐early historic Pecos Pueblo with those of present‐day Indigenous individuals from New Mexico. Materials and Methods Femora and tibiae of 126 adults from Pecos Pueblo and 226 present‐day adults were included in the study. Cross‐sectional diaphyseal properties—areas and second moments of area—were obtained from past studies of the Pecos Pueblo skeletal sample, and from computed tomography scans of recently deceased individuals in the present‐day sample. Results Femora and tibiae from Pecos individuals are stronger relative to body size than those of present‐day Indigenous individuals. Present‐day individuals are taller but not wider, and this body shape difference affects cross‐sectional shape, more strongly proximally. The tibia shows anteroposterior strengthening among Pecos individuals, especially among males. Sexual dimorphism in midshaft bone shape is stronger within the Pecos Pueblo sample. With aging, Pecos individuals show more medullary expansion but also more subperiosteal expansion than present‐day individuals, maintaining bone strength despite cortical thinning. Discussion Higher activity levels, carried out over rough terrain and throughout adult life, likely explain the relatively stronger lower limb bones of the Pecos individuals, as well as their greater subperiosteal expansion with aging. Greater sexual dimorphism in bone structure among Pecos individuals potentially reflects greater gender‐based differences in behavioral patterns.
Year:
2024
Year:
2024
At the headwaters of the Yenisei River in Tuva and northern Mongolia, nomadic pastoralists move between camps in a seasonal rotation that facilitates their animals' access to high-quality grasses and shelter. The use and informal ownership of these camps depending on season helps illustrate evolutionary and ecological principles underlying variation in property relations. Given relatively stable patterns of precipitation and returns to capital improvement, families generally benefit from reusing the same camps year after year. We show that locations with higher economic defensibility and capital investment—winter camps and camps located in mountain/river valleys—are claimed and inherited more frequently than summer camps and camps located in open steppe. Camps are inherited patrilineally and matrilineally at a ratio of 2 : 1. Despite its practical importance, camp inheritance is not associated with livestock wealth today, which is better predicted by education and wealth outside the pastoral economy. The relationship between the livestock wealth of parents and their adult children is significantly positive, but relatively low compared to other pastoralists. The degree of inequality in livestock wealth, however, is very close to that of other pastoralists. This is understandable considering the durability and defensibility of animal wealth and economies of scale common across pastoralists. This article is part of the theme issue ‘Evolutionary ecology of inequality’.
Year:
2023
Year:
2023
Collaborators (30)
Yuting Lu
New York University
Graham Mann
Professor
University of Sydney
Shaofeng Yan
-
John Ziker
Professor
Boise State University
Yongzhao Shao
New York University Grossman School of Medicine
Cheryl Thompson
Professor and Associate Director for Population Sciences, Penn State Cancer Institute
Pennsylvania State University
Paul L. Hooper
Adjunct Associate Professor of Anthropology
University of New Mexico
Christopher I. Amos
Associate Director for Population and Data Science
Baylor College of Medicine
Jessica Valdez
Associate Professor; Attending Physician
University of New Mexico
Pauline Funchain
Stanford University
Marcus Bosenberg
Professor
Yale University
Marianne Berwick
Professor
University of New Mexico
David Ollila
Professor of Surgery
University of North Carolina at Chapel Hill
Marc Ernstoff
Chief
National Institutes of Health
Anne E Cust
Deputy Director, The Daffodil Centre
University of Sydney
Matthew Turner
Lecturer
Stanford University
David Polsky
Alfred W. Kopf, M.D. Professor of Dermatologic Oncology and Professor (Clinical) of Pathology (Academic)
NYU School of Medicine
Tea Jashashvili
Assistant Professor
University of Southern California Keck School of Medicine
Tim Lee
The University of British Columbia
Pei-Fen Kuan
Professor
Stony Brook University
Paul Googe
Professor and Laboratory Director
University of North Carolina at Chapel Hill
Stefani A. Crabtree
Utah State University
Hoda Anton-Culver
Professor and Chair
University of California, Irvine
James Wilmott
Associate Professor
The University of Sydney Library
Iman Osman
NYU Langone Health
Eva Hernando
Professor
NYU Langone Medical Center
Sheri L. Holmen
Professor
University of Utah Health Sciences Center
James Jones
Professor
Stanford University
Richard A. Scolyer
Faculty Member
University of Sydney
E. Nagore
Profesor Asociado
Universidad Católica de Valencia San Vicente Mártir Facultad de Medicina Facultad de Medicina y Odontología
Make your next move.
Prepare your application
Review drafts before you send them.